Literature DB >> 12493743

Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor.

Dong Yu1, Hiroshi Watanabe, Hitoshi Shibuya, Masahiko Miura.   

Abstract

The insulin-like growth factor I receptor (IGF-IR) has the ability to confer clonogenic radioresistance following ionizing irradiation. We attempted to determine the downstream pathways involved in IGF-IR-mediated radioresistance and used mouse embryo fibroblasts deficient in endogenous IGF-IR (R-) as recipients for a number of mutant IGF-IRs. Mutational analysis revealed that the tyrosine at residue 950 (Tyr-950) of IGF-IR, as well as the C-terminal domain, are required for radioresistance and that both domains must be mutated to abrogate the phenotype. Furthermore, the contribution of downstream pathways was analyzed by combining the use of wild-type or Tyr-950 and C-terminal mutants with specific inhibitors of phosphatidylinositol 3'-kinase (PI3-K) or mitogen-activated protein extracellular signal-regulated kinase (ERK) kinase (MEK). Radioresistance could be induced by IGF-IR as long as the ability of the receptor to stimulate the MEK/ERK pathway was retained. This was confirmed by the expression of constitutively active MEK in R- cells. The ability to stimulate the PI3-K pathway alone was not sufficient, but PI3-K activation coupled with MEK/ERK pathway-independent signals from the C terminus was able to induce radioresistance. Taken together, these results indicate that the IGF-IR-mediated radioresistant signaling mechanism progresses through redundant downstream pathways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12493743     DOI: 10.1074/jbc.M209809200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.

Authors:  Jordi Rodon; Victoria DeSantos; Robert Jean Ferry; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

2.  A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells.

Authors:  Kota Tsuruya; Hiromi Chikada; Kinuyo Ida; Kazuya Anzai; Tatehiro Kagawa; Yutaka Inagaki; Tetsuya Mine; Akihide Kamiya
Journal:  Stem Cells Dev       Date:  2015-04-28       Impact factor: 3.272

3.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

4.  Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.

Authors:  Xianke Zeng; Deepali Sachdev; Hua Zhang; Martine Gaillard-Kelly; Douglas Yee
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 5.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

6.  MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3).

Authors:  Chuan He Yang; Junming Yue; Susan R Pfeffer; Meiyun Fan; Elena Paulus; Amira Hosni-Ahmed; Michelle Sims; Sohail Qayyum; Andrew M Davidoff; Charles R Handorf; Lawrence M Pfeffer
Journal:  J Biol Chem       Date:  2014-07-24       Impact factor: 5.157

Review 7.  Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention.

Authors:  T J Fitzgerald; Tao Wang; Hira Lal Goel; Jiayi Huang; Gary Stein; Jane Lian; Roger J Davis; Steven Doxsey; K C Balaji; Jesse Aronowitz; Lucia R Languino
Journal:  Expert Rev Anticancer Ther       Date:  2008-06       Impact factor: 4.512

8.  IGF and insulin receptor signaling in breast cancer.

Authors:  Antonino Belfiore; Francesco Frasca
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-19       Impact factor: 2.673

9.  MVP expression in the prediction of clinical outcome of locally advanced oral squamous cell carcinoma patients treated with radiotherapy.

Authors:  Luis Alberto Henríquez-Hernández; Mercedes Moreno; Agustín Rey; Marta Lloret; Pedro C Lara
Journal:  Radiat Oncol       Date:  2012-08-29       Impact factor: 3.481

10.  Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.

Authors:  C S Higano; J Berlin; M Gordon; P LoRusso; S Tang; A Dontabhaktuni; J D Schwartz; J Cosaert; J M Mehnert
Journal:  Invest New Drugs       Date:  2015-03-07       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.